Skip to main content
Erschienen in: best practice onkologie 3/2023

01.02.2023 | Telemedizin | Topic

Digitale Anwendungen in der Onkologie

Kann ein Klick den Arztbesuch ersetzen?

verfasst von: Dr. Davide Scafa, Prof. Dr. Med. N. Nicolay, Prof. Dr. Med. Frank A. Giordano

Erschienen in: best practice onkologie | Ausgabe 3/2023

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hintergrund

Die digitale Patientenversorgung stellt eine der spannendsten zukünftigen Entwicklungen in der Onkologie dar.

Ziel der Arbeit

Ziel des Übersichtartikels ist es, die wesentlichen Aspekte der eHealth, v. a. in der Onkologie, aufzuzeigen.

Material und Methode

Relevante wissenschaftliche und fachliche Beiträge zum Thema eHealth im onkologischen Kontext wurden gesichtet.

Ergebnisse

Die wissenschaftlichen Daten und Erfahrungen zur digitalen Patientenversorgung konsolidieren sich zunehmend. Die Vorteile, aber auch einige Einschränkungen, werden in verschiedenen Quellen hervorgehoben, mit überwiegend positiven und ermutigenden Bewertungen, die zeigen, dass sich die Telemedizin zu einem bedeutsamen Behandlungsmittel in der Versorgung von Krebspatienten entwickelt.

Schlussfolgerung

Die Digitalisierung im Gesundheitswesen ist teilweise bereits in den klinischen Alltag integriert und verfügt über enormes Potenzial, trotz einiger aufgezeigter Limitationen. Es sind jedoch kontinuierliche Investitionen in die Infrastruktur und weitere wissenschaftliche Daten erforderlich.
Literatur
2.
Zurück zum Zitat MacBride SK, Whyte F (1998) Survivorship and the cancer follow-up clinic. Eur J Cancer Care (Engl) 7(1):47–55CrossRefPubMed MacBride SK, Whyte F (1998) Survivorship and the cancer follow-up clinic. Eur J Cancer Care (Engl) 7(1):47–55CrossRefPubMed
3.
Zurück zum Zitat Wozniak AM, Rallis KS, Elkaddoum R (2021) Telemedicine health disparities in oncology care. Future Oncol 17(14):1695–1698CrossRefPubMed Wozniak AM, Rallis KS, Elkaddoum R (2021) Telemedicine health disparities in oncology care. Future Oncol 17(14):1695–1698CrossRefPubMed
5.
Zurück zum Zitat Expertenkommission Forschung und Innovation (2022) Gutachten zu Forschung, Innovation und technologischer Leistungsfähigkeit Deutschlands 2022 Expertenkommission Forschung und Innovation (2022) Gutachten zu Forschung, Innovation und technologischer Leistungsfähigkeit Deutschlands 2022
6.
Zurück zum Zitat Albino de Queiroz D et al (2021) Internet of things in active cancer treatment: a systematic review. J Biomed Inform 118:103814CrossRefPubMed Albino de Queiroz D et al (2021) Internet of things in active cancer treatment: a systematic review. J Biomed Inform 118:103814CrossRefPubMed
7.
Zurück zum Zitat Germini F et al (2022) Accuracy and acceptability of wrist-wearable activity-tracking devices: systematic review of the literature. J Med Internet Res 24(1):e30791CrossRefPubMedPubMedCentral Germini F et al (2022) Accuracy and acceptability of wrist-wearable activity-tracking devices: systematic review of the literature. J Med Internet Res 24(1):e30791CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Millstine DM et al (2019) Use of a wearable EEG headband as a meditation device for women with newly diagnosed breast cancer: a randomized controlled trial. Integr Cancer Ther 18:1534735419878770CrossRefPubMedPubMedCentral Millstine DM et al (2019) Use of a wearable EEG headband as a meditation device for women with newly diagnosed breast cancer: a randomized controlled trial. Integr Cancer Ther 18:1534735419878770CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Basch E et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefPubMed Basch E et al (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34(6):557–565CrossRefPubMed
10.
Zurück zum Zitat Denis F et al (2017) Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst 109(9):djx29CrossRef Denis F et al (2017) Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. J Natl Cancer Inst 109(9):djx29CrossRef
12.
Zurück zum Zitat Schaeffer D, Berens E‑M, Gille S, Griese L, Klinger J, de Sombre S, Vogt D, Hurrelmann K (2021) Gesundheitskompetenz der Bevölkerung in Deutschland vor und während der Corona Pandemie: Ergebnisse des HLS-GER 2. Universität Bielefeld, Interdisziplinäres Zentrum für Gesundheitskompetenzforschung, Bielefeld Schaeffer D, Berens E‑M, Gille S, Griese L, Klinger J, de Sombre S, Vogt D, Hurrelmann K (2021) Gesundheitskompetenz der Bevölkerung in Deutschland vor und während der Corona Pandemie: Ergebnisse des HLS-GER 2. Universität Bielefeld, Interdisziplinäres Zentrum für Gesundheitskompetenzforschung, Bielefeld
13.
Zurück zum Zitat Giordano FA et al (2020) Digital follow-up and the perspective of patient-centered care in oncology: What’s the problem? Oncology 98(6):379–385CrossRefPubMed Giordano FA et al (2020) Digital follow-up and the perspective of patient-centered care in oncology: What’s the problem? Oncology 98(6):379–385CrossRefPubMed
14.
Zurück zum Zitat Vodicka E et al (2015) Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007–2013). Contemp Clin Trials 43:1–9CrossRefPubMed Vodicka E et al (2015) Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007–2013). Contemp Clin Trials 43:1–9CrossRefPubMed
15.
Zurück zum Zitat Bottomley A et al (2016) Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 17(11):e510–e514CrossRefPubMed Bottomley A et al (2016) Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncol 17(11):e510–e514CrossRefPubMed
17.
Zurück zum Zitat American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14(2):671–679CrossRef American Society of Clinical Oncology (1996) Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 14(2):671–679CrossRef
18.
Zurück zum Zitat Di Maio M et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915CrossRefPubMed Di Maio M et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915CrossRefPubMed
19.
Zurück zum Zitat Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909CrossRefPubMed Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903–909CrossRefPubMed
20.
Zurück zum Zitat Cirillo M et al (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20(12):1929–1935CrossRefPubMed Cirillo M et al (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient’s self-reported questionnaire. Ann Oncol 20(12):1929–1935CrossRefPubMed
22.
Zurück zum Zitat Bhattacharya IS et al (2019) Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiother Oncol 134:220–230CrossRefPubMedPubMedCentral Bhattacharya IS et al (2019) Can patient-reported outcomes be used instead of clinician-reported outcomes and photographs as primary endpoints of late normal tissue effects in breast radiotherapy trials? Results from the IMPORT LOW trial. Radiother Oncol 134:220–230CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Basch E et al (2020) Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine cancer care: findings from the PRO-TECT trial. JCO Clin Cancer Inform 4:947–957CrossRefPubMed Basch E et al (2020) Clinical utility and user perceptions of a digital system for electronic patient-reported symptom monitoring during routine cancer care: findings from the PRO-TECT trial. JCO Clin Cancer Inform 4:947–957CrossRefPubMed
24.
Zurück zum Zitat Basch E et al (2022) Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA 327(24):2413–2422CrossRefPubMedPubMedCentral Basch E et al (2022) Effect of electronic symptom monitoring on patient-reported outcomes among patients with metastatic cancer: a randomized clinical trial. JAMA 327(24):2413–2422CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Zamboglou C et al (2021) PSMA-PET/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-SBRT): study protocol of a randomized, multicentric phase III trial. Cancers (Basel) 13(22):5795CrossRefPubMed Zamboglou C et al (2021) PSMA-PET/MRI-based focal dose escalation in patients with primary prostate cancer treated with stereotactic body radiation therapy (hypofocal-SBRT): study protocol of a randomized, multicentric phase III trial. Cancers (Basel) 13(22):5795CrossRefPubMed
27.
Zurück zum Zitat Spohn SKB et al (2022) Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients. BMC Cancer 22(1):337CrossRefPubMedPubMedCentral Spohn SKB et al (2022) Feasibility, pitfalls and results of a structured concept-development phase for a randomized controlled phase III trial on radiotherapy in primary prostate cancer patients. BMC Cancer 22(1):337CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Triberti S et al (2019) eHealth for improving quality of life in breast cancer patients: a systematic review. Cancer Treat Rev 74:1–14CrossRefPubMed Triberti S et al (2019) eHealth for improving quality of life in breast cancer patients: a systematic review. Cancer Treat Rev 74:1–14CrossRefPubMed
29.
Zurück zum Zitat Freyer DR et al (2022) Lack of concordance in symptomatic adverse event reporting by children, clinicians, and caregivers: implications for cancer clinical trials. J Clin Oncol 40(15):1623–1634CrossRefPubMed Freyer DR et al (2022) Lack of concordance in symptomatic adverse event reporting by children, clinicians, and caregivers: implications for cancer clinical trials. J Clin Oncol 40(15):1623–1634CrossRefPubMed
30.
Zurück zum Zitat Rosenberg AR (2022) We cannot change what we cannot see: a rationale for patient-reported outcomes in pediatric oncology clinical research. J Clin Oncol 40(15):1601–1603CrossRefPubMed Rosenberg AR (2022) We cannot change what we cannot see: a rationale for patient-reported outcomes in pediatric oncology clinical research. J Clin Oncol 40(15):1601–1603CrossRefPubMed
31.
Zurück zum Zitat Lewis J, Ray P, Liaw ST (2016) Recent worldwide developments in ehealth and mHealth to more effectively manage cancer and other chronic diseases—a systematic review. Yearb Med Inform 25(01):93–108CrossRef Lewis J, Ray P, Liaw ST (2016) Recent worldwide developments in ehealth and mHealth to more effectively manage cancer and other chronic diseases—a systematic review. Yearb Med Inform 25(01):93–108CrossRef
32.
Zurück zum Zitat Li J et al (2021) Effect of telehealth interventions on quality of life in cancer survivors: a systematic review and meta-analysis of randomized controlled trials. Int J Nurs Stud 122:103970CrossRefPubMed Li J et al (2021) Effect of telehealth interventions on quality of life in cancer survivors: a systematic review and meta-analysis of randomized controlled trials. Int J Nurs Stud 122:103970CrossRefPubMed
33.
36.
Zurück zum Zitat Ghani Z et al (2020) The cost-effectiveness of mobile health (mHealth) interventions for older adults: systematic review. Int J Environ Res Public Health 17(15):5290CrossRefPubMedPubMedCentral Ghani Z et al (2020) The cost-effectiveness of mobile health (mHealth) interventions for older adults: systematic review. Int J Environ Res Public Health 17(15):5290CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Jones G et al (2018) Evaluating the impact of a ‘virtual clinic’ on patient experience, personal and provider costs of care in urinary incontinence: a randomised controlled trial. PLoS ONE 13(1):e189174CrossRefPubMedPubMedCentral Jones G et al (2018) Evaluating the impact of a ‘virtual clinic’ on patient experience, personal and provider costs of care in urinary incontinence: a randomised controlled trial. PLoS ONE 13(1):e189174CrossRefPubMedPubMedCentral
Metadaten
Titel
Digitale Anwendungen in der Onkologie
Kann ein Klick den Arztbesuch ersetzen?
verfasst von
Dr. Davide Scafa
Prof. Dr. Med. N. Nicolay
Prof. Dr. Med. Frank A. Giordano
Publikationsdatum
01.02.2023
Verlag
Springer Medizin
Schlagwort
Telemedizin
Erschienen in
best practice onkologie / Ausgabe 3/2023
Print ISSN: 0946-4565
Elektronische ISSN: 1862-8559
DOI
https://doi.org/10.1007/s11654-023-00468-x

Weitere Artikel der Ausgabe 3/2023

best practice onkologie 3/2023 Zur Ausgabe

Editorial

Editorial

onko-aktuell

onko-aktuell

Kongresse – wichtig zu wissen

Wichtige Studien vom ASH 2022

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.